Paolo Tarantino1,2, Giuseppe Curigliano3,4. 1. Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy. 2. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. 3. Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Via Ripamonti 435, 20141, Milan, Italy. Giuseppe.curigliano@ieo.it. 4. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Giuseppe.curigliano@ieo.it.
Authors: Otto Metzger Filho; Daniel G Stover; Sarah Asad; Peter J Ansell; Mark Watson; Sibylle Loibl; Charles E Geyer; Junu Bae; Katharine Collier; Mathew Cherian; Joyce O'Shaughnessy; Michael Untch; Hope S Rugo; Jens B Huober; Mehra Golshan; William M Sikov; Gunter von Minckwitz; Priya Rastogi; David Maag; Norman Wolmark; Carsten Denkert; W Fraser Symmans Journal: JAMA Oncol Date: 2021-04-01 Impact factor: 31.777